[{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Covis Pharma \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Norgine"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Covis Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Ciraparantag Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Ciraparantag Holdings","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Ciraparantag Holdings"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.28999999999999998,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Norgine"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Evening Primrose Oil","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"LUXEMBOURG","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Covis Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"LUXEMBOURG","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Covis Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Covis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Ferrous Sulfate","moa":"Iron stores","graph1":"Neurology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Palatin Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Palatin Technologies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Covis Pharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Aclidinium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.27000000000000002,"dosageForm":"Powder for Inhalation","sponsorNew":"Covis Pharma \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Covis Pharma"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Aclidinium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.27000000000000002,"dosageForm":"Powder for Inhalation","sponsorNew":"Covis Pharma \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Covis Pharma"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aclidinium Bromide","moa":"||Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Covis Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"LUXEMBOURG","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Covis Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"LUXEMBOURG","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Covis Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Digoxin","moa":"Sodium\/potassium-transporting ATPase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nitroglycerin","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Covis Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dehydroepiandrosterone","moa":"steroids (androgens","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Suppository","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Endoceutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Prasterone","moa":"steroids (androgens","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Insert","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Endoceutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Prasterone","moa":"steroids (androgens","graph1":"Oncology","graph2":"Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Millicent Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Divestment","leadProduct":"Prasterone","moa":"steroids (androgens","graph1":"Neurology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Millicent Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Millicent Pharma"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase IV","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.65000000000000002,"dosageForm":"Injection","sponsorNew":"Covis Pharma \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Covis Pharma"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.65000000000000002,"dosageForm":"Injection","sponsorNew":"Covis Pharma \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Covis Pharma"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"AMAG Pharmaceuticals \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Olivia Cardenas-Trowers, M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Prasterone","moa":"steroids (androgens","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Insert","sponsorNew":"AMAG Pharmaceuticals \/ Olivia Cardenas-Trowers, M.D.","highestDevelopmentStatusID":"10","companyTruncated":"AMAG Pharmaceuticals \/ Olivia Cardenas-Trowers, M.D."}]
Find Clinical Drug Pipeline Developments & Deals by Covis Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
